All News

Rapid genetic test for IVF identifies FSHR variant in 60 minutes, guiding IVF hormone selection and improving in vitro fertilization success.

GLP-1s and SGLT2s were associated with improved kidney outcomes and no increased safety risks in patients with T1D and CKD.

A survey of marketplace enrollees revealed that they expect to cut back on basic household expenses to keep insurance coverage.

Male patients and those from minoritized racial and ethnic groups face longer times to treatment, especially in urban areas.

Patients with primary biliary cholangitis (PBC) can use linerixibat to address cholestatic pruritus, which up to 89% of patients with PBC experience.

A phase 3 clinical trial found that the ustekinumab biosimilar CT-P43 demonstrated equivalent efficacy, safety, and immunogenicity to reference ustekinumab in patients with moderate to severe plaque psoriasis.

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

A new meta-analysis links menopausal hormone therapy to higher breast cancer risk with estrogen-progestin therapy, while estrogen-only therapy may lower risk.

New research shows that cardiovascular protection from GLP-1 receptor agonists such as semaglutide and tirzepatide diminishes within months of discontinuation.

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity.

Patients with multiple sclerosis valued both occupational therapy and physiotherapy as means of addressing their condition.

Study supports broader use of transient elastography to detect advanced liver fibrosis in patients with metabolic dysfunction–associated steatotic liver disease.

Icotrokinra is the first and only interleukin-23–targeted oral peptide approved for plaque psoriasis.

Smarter therapies, evolving frailty tools, and more inclusive trials are finally extending myeloma's survival gains to older adults.

A federal court blocked RFK Jr's vaccine agenda, freezing the ACIP shakeup and safeguarding child vaccine access as the legal fight over vaccines intensifies.

Subcutaneous mosunetuzumab simplifies the delivery of the bispecific therapy for patients with relapsed/refractory follicular lymphoma, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Vaccine schedule shifts may widen gaps; learn how safety-net workflows and community education counter misinformation and boost uptake.

Long-term adherence to healthy behaviors reduces the risk of cardiovascular disease and type 2 diabetes, even among individuals taking antihypertensive medications.

The complete response letter marks the second time that reproxalap, a medication for use in dry eye disease, has been rejected by the FDA.

Study links PFAS and forever chemicals in children and teens to lower bone density in adolescents—especially girls—highlighting critical exposure windows.

Researchers find that epigenetic changes from the famine caused CV and mental health effects for 3 to 4 generations on both sides of the Atlantic.

Rising global temperatures are silently driving a sedentary crisis, and the world’s most vulnerable populations are paying the steepest price.

Severe COVID-19 was rare in patients with multiple sclerosis even when vaccine responses were impaired.

Secukinumab becomes the only IL-17A inhibitor approved for this population and the first new mechanism in the indication in nearly a decade.

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, supporting potential pediatric label expansion.